about
Oral antineoplastic agents: how do we care about adherence?The development and acceptability of symptom management quality improvement reports based on patient-reported data: an overview of methods used in PROSSES.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and DevelopmentImpact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts.Improving outcomes in cancer patients on oral anti-cancer medications using a novel mobile phone-based intervention: study design of a randomized controlled trial.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis.Reimbursement challenges with cancer immunotherapeutics.Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation.Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.Lipid nanoparticles for cancer therapy: state of the art and future prospects.Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Drug interactions with sunitinib.Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.Optimizing cancer care through mobile health.Oral Antineoplastic Agents: Assessing the Delay in Care.A Bridging Opportunities Work-frame to develop mobile applications for clinical decision making.A review of semi-synthetic biopolymer complexes: modified polysaccharide nano-carriers for enhancement of oral drug bioavailability.Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles.Intracellular Ca2+ release mediates cationic but not anionic poly(amidoamine) (PAMAM) dendrimer-induced tight junction modulation.Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer.Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats.Oral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse models.Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial.New oral targeted therapies for metastatic breast cancer disrupt the traditional patients' management-A healthcare providers' view.National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.
P2860
Q28082909-9112FCAD-BFB8-4648-80D7-106CF48F0F77Q31110331-28A5E94F-8623-4886-A3F0-CE62E0AD3AF1Q33408664-941AEDDB-FBEF-426D-B544-7533A34E1360Q33454095-116D04E4-FE8C-47A6-BF5F-BF1C582AA734Q33847820-CC31EF65-0EF5-47A5-8085-89268AC6D3CDQ34974434-30D597C1-65D7-4A02-8823-6B239BCA8D81Q35023711-C4E2B6F1-9A3A-42AE-8FF3-8101FEEE88F9Q35444531-B9E50529-E084-491C-AA22-30FEC2BB6A7AQ36631334-1320D312-F2DF-4951-BD85-454B8AC4178AQ37474599-44BB4D09-A5EA-4B2A-BF13-596D8199F62EQ37965653-014F5DEB-E92F-4153-8280-CEBE0E3889DEQ38040884-55DE2FB9-CC28-482F-8EBB-637556C0962AQ38042003-E818B866-A0F6-4F4E-B46C-398CB1E81724Q38082728-3E57F54A-90F9-4191-B9F4-798E5D136253Q38176853-2CFFE0C2-3C26-4E3F-A239-42828315F45BQ38258719-B9080738-A858-4402-A176-9F2E18536391Q38343257-C7758D00-D2A3-4BFE-B61D-83ABB7FEFDD7Q38647171-6FC73DD3-3661-4647-8D8C-23B6D7BF25BBQ38776997-0F771BFF-68D5-4C2B-BC3A-4A62B7CF0540Q38911933-FD8961B3-C953-441E-9417-81E9C79E92DCQ39041183-470017A6-EB43-42C2-BC55-B15EAB615D63Q39227267-7D38DD17-9DE9-4A9E-B932-C8DE1536DD78Q41623664-52123ECF-A739-4B0D-B348-381834F90C70Q43541374-FE1F42BE-2F35-4334-8104-CED05D9AF2A2Q45729918-96214077-90C6-42F7-ADEC-4405972D223AQ45939780-DC8BB3E1-CDB0-4C1F-870B-C5EDE5FF5775Q47831792-8E86E38E-1571-4C71-B9AD-2A86246C40EEQ48115704-40E596B6-AAC0-4ABE-8419-2BDF3D6C5B97Q48296939-888FDCAC-DAF0-4467-A6E7-2C0A45419B00Q55278614-B6F82A57-BF5D-48FA-A303-1068D00F609F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anticancer oral therapy: emerging related issues.
@en
Anticancer oral therapy: emerging related issues.
@nl
type
label
Anticancer oral therapy: emerging related issues.
@en
Anticancer oral therapy: emerging related issues.
@nl
prefLabel
Anticancer oral therapy: emerging related issues.
@en
Anticancer oral therapy: emerging related issues.
@nl
P2093
P1476
Anticancer oral therapy: emerging related issues
@en
P2093
Calogero Buscarino
Elena Collovà
Francesco Ferraù
Giuseppe Luigi Banna
Helga Lipari
Paolo Tralongo
Pietro Giuffrida
Rosaria Condorelli
P304
P356
10.1016/J.CTRV.2010.04.005
P577
2010-06-08T00:00:00Z